MedTrace Logo

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-03-19

No results posted yet for this study

Summary

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.

Conditions

  • Seizures
  • Primary Motor Cortex
  • Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
  • Brain Metastases, Adult
  • Brain Metastases From Extra-cranial Solid Tumors

Interventions

DRUG

Levetiracetam (Keppra)

Patients will be randomized to receive levetiracetam/ASM or to receive no ASM therapy

Sponsors & Collaborators

Principal Investigators

  • Ayal A Aizer, MD, MHS · Dana-Farber/Brigham and Women's Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2029-02-28
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07130786 on ClinicalTrials.gov